Array BioPharma Inc

Type: Company
Name: Array BioPharma Inc
Nationality: United States
Web Address: http://www.arraybiopharma.com/
First reported Sep 19 2014 - Updated Sep 19 2014 - 1 reports

Array BioPharma, Inc. (ARRY) Appoints Victor Sandor, M.D., As Chief Medical Officer

BOULDER, Colo., Sept. 11, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients with cancer, today announced ... [Published FierceBiotech - Sep 19 2014]
First reported Sep 16 2014 - Updated Sep 16 2014 - 1 reports

Array appoints Victor Sandor chief medical officer

Array Biopharma has named Victor Sandor as its new chief medical officer, handing him responsibility for leading clinical, medical and regulatory strategy and operations across its Array portfolio.This includes the Colorado, US-based company's binimetinic, ... [Published PMLive - Sep 16 2014]
First reported Sep 15 2014 - Updated Sep 15 2014 - 1 reports

Allergic Rhinitis Treatment Market Global Technology Forecast 2019

Allergic Rhinitis is a chronic inflammatory disease of the nasal cavity which causes respiratory problems and affects all age groups. Common symptoms of the disease include sneezing, sore throat, nasal itching and blocked or running nose. The disease ... [Published MyNewsDesk - Sep 15 2014]
First reported Sep 12 2014 - Updated Sep 12 2014 - 2 reports

Loxo Oncology Announces Second Quarter 2014 Financial Results

STAMFORD, Conn., Sept. 12, 2014 (GLOBE NEWSWIRE) -- Loxo Oncology, Inc. (Nasdaq:LOXO) ("Loxo"), a biopharmaceutical company focused on developing targeted cancer therapies for genetically-defined populations, today reported financial results for the quarter ... [Published Virtual Strategy Magazine - Sep 12 2014]
First reported Sep 11 2014 - Updated Sep 12 2014 - 5 reports

Array BioPharma hires Dr Victor Sandor as CMO for late-stage clinical programmes

Biopharmaceutical company Array BioPharma (NasdaqGM:ARRY) reported on Thursday that it has appointed Dr Victor Sandor, MD as its chief medical officer. In his new role, Dr Sandor will replace the company's chief medical officer Dr Michael Needle.Dr Sandor ... [Published Individual.com - Sep 12 2014]
First reported Sep 11 2014 - Updated Sep 12 2014 - 1 reports

Inflammatory Pain Therapeutics Pipeline Review 2014 - 36 Companies and 67 Drug Profiles

Research and Markets (http://www.researchandmarkets.com/research/v44nlf/inflammatory_pain) has announced the addition of the "Inflammatory Pain - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the ... [Published Individual.com - Sep 11 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

Array BioPharma's (ARRY) CEO Ron Squarer at Morgan Stanley 2014 Global Healthcare Conference (Transcript)

Matthew Palmer - Morgan StanleyWe'll go ahead and get started now. Good afternoon and welcome to the Morgan Stanley Global Healthcare Conference. My name is Matthew Palmer and I am a member of the Biotechnology Equity Research team here at Morgan Sta ... [Published Seeking Alpha - Sep 10 2014]
First reported Sep 10 2014 - Updated Sep 10 2014 - 1 reports

June 2015 Options Now Available For Array BioPharma (ARRY)

Investors in Array BioPharma Inc. (ARRY) saw new options begin trading today, for the June 2015 expiration.. ... [Published Crawford Financial Planning - Sep 10 2014]
First reported Sep 03 2014 - Updated Sep 04 2014 - 3 reports

Array BioPharma To Present At The Morgan Stanley 2014 Global Healthcare Conference

BOULDER, Colo.About Array BioPharmaArray BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven Phase 3 or pivotal studies ... [Published ADVFN UK - Sep 03 2014]
First reported Sep 01 2014 - Updated Sep 01 2014 - 1 reports

Array BioPharma Q4 net loss up

Array BioPharma Inc., a biopharmaceutical company, has reported that net loss for the fourth quarter ended June 30, 2014 was $28.24 million, or $0.22 loss per share, compared to a net loss of $17.65 million, or $0.15 loss per share, for the same quarter ... [Published Individual.com - Sep 01 2014]
First reported Aug 28 2014 - Updated Aug 28 2014 - 2 reports

Array Biopharma Inc. Files SEC Form POSASR, Post-effective Amendment To An Automatic Shelf Registration Statement (Aug. 14, 2014)

By a News Reporter-Staff News Editor at Biotech Week -- According to news reporting originating from Washington, D.C., by NewsRx journalists, a U.S. Securities and Exchange Commission (SEC) filing by Array Biopharma Inc. (Form POSASR) was posted on August ... [Published Crawford Financial Planning - Aug 28 2014]
First reported Aug 25 2014 - Updated Aug 25 2014 - 2 reports

Five Billionaire-Owned Biotech Stocks You Could Acquire for 100%

08/25/14 - 02:18 PM EDTNEW YORK ( TheStreet ) -- Today, the biotech stock InterMune   ( ITMN ) was acquired by Roche  for a 40% premium.That 40% premium is in addition to the nearly 70% gain the stock has experienced this month, driven by the takeover ... [Published TheStreet.com - Aug 25 2014]

Quotes

...efforts as we advance our late-stage, wholly-owned assets toward commercialization," said Ron Squarer, Chief Executive Officer, Array BioPharma.  "With the possible near-term return of binimetinib to Array, his expertise will have significant impact on our long-term success."
"It has been an exciting and productive quarter for the company," said Josh Bilenker, MD, Chief Executive Officer of Loxo Oncology. "We continue to enroll our Phase 1 trial for LOXO-101, and we are working well alongside our collaboration partner Array BioPharma to advance our pipeline. Subsequent to the quarter's end, we completed our initial public offering, which generated $72.4 million in net proceeds. We believe we are well-positioned to advance our science, and hopefully, bring new and important medicines to cancer patients."
"Maintenance therapy with lenalidomide, as compared with no maintenance therapy, significantly reduced the risk of disease progression" they add
...08 million, compared to $69.58 million for the same period ended June 30, 2013. Ron Squarer, CEO of Array, noted, "The Array-invented MEK inhibitors, binimetinib and selumetinib, are currently enrolling six Phase III trials, and each of our partners has announced expectations for regulatory filings next year. In addition, we continue to advance our wholly-owned filanesib program, which has the potential to be an important novel treatment for patients with multiple myeloma. Given the progress on our key programs and the possible return of binimetinib to Array, we are looking forward to an exciting year."

More Content

All (82) | News (48) | Reports (0) | Blogs (27) | Audio/Video (0) | Fact Sheets (0) | Press Releases (7)
sort by: Date | Relevance
Array BioPharma, Inc. (ARRY) Appoints Victor Sa... [Published FierceBiotech - Sep 19 2014]
Array appoints Victor Sandor chief medical officer [Published PMLive - Sep 16 2014]
Allergic Rhinitis Treatment Market Global Techn... [Published MyNewsDesk - Sep 15 2014]
Array BioPharma hires Dr Victor Sandor as CMO f... [Published Individual.com - Sep 12 2014]
New medical chief at Array Bio [Published Seeking Alpha - Sep 12 2014]
Loxo Oncology Announces Second Quarter 2014 Fin... [Published Virtual Strategy Magazine - Sep 12 2014]
Loxo Oncology Announces Second Quarter 2014 Fin... [Published Pettinga Financial Advisors - Sep 12 2014]
Array BioPharma Appoints Victor Sandor, M.D., A... [Published Bio-Medicine - Sep 12 2014]
Array BioPharma : Appoints Victor Sandor, M.D.,... [Published 4 Traders - Sep 11 2014]
Array BioPharma Appoints Victor Sandor, M.D., A... [Published PR Newswire: General Business - Sep 11 2014]
Inflammatory Pain Therapeutics Pipeline Review ... [Published Individual.com - Sep 11 2014]
Array BioPharma's (ARRY) CEO Ron Squarer at Mor... [Published Seeking Alpha - Sep 10 2014]
June 2015 Options Now Available For Array BioPh... [Published Crawford Financial Planning - Sep 10 2014]
ASLAN Pharmaceuticals Pte Ltd Doses First Patie... [Published BioSpace - Sep 09 2014]
Stem Cell Transplant With Melphalan Preferred i... [Published American Journal of Public Health - Sep 04 2014]
Array BioPharma To Present At The Morgan Stanle... [Published ADVFN UK - Sep 03 2014]
Array BioPharma To Present At The Morgan Stanle... [Published Michigan Live - Sep 03 2014]
Array BioPharma To Present At The Morgan Stanle... [Published PR Newswire: Health - Sep 03 2014]
Array BioPharma Q4 net loss up [Published Individual.com - Sep 01 2014]
Array Biopharma Inc. Files SEC Form POSASR, Pos... [Published Crawford Financial Planning - Aug 28 2014]
Array Biopharma Inc. Files SEC Form POSASR, Pos... [Published HispanicBusiness.com - Aug 28 2014]
Patent Issued for Arylamino N-Heteraryl Compoun... [Published Pharmacy Choice - Aug 27 2014]
Five Billionaire-Owned Biotech Stocks You Could... [Published TheStreet.com - Aug 25 2014]
Five Billionaire-Owned Biotech Stocks You Could... [Published The Street Latest - Aug 25 2014]
Oncothyreon Reports Second Quarter 2014 Financi... [Published HispanicBusiness.com - Aug 20 2014]
First Week of October 18th Options Trading For ... [Published TVNewsCheck - Aug 19 2014]
Technical Summary on Biotech Equities -- Alkerm... [Published Financial Services - Aug 18 2014]
TNF Inhibitors for RA: No Link to Breast Cancer [Published Diabetes Care - Aug 18 2014]
Array BioPharma Falls Despite Narrower-than-Exp... [Published Yahoo! Finance - Aug 15 2014]
ARRAY BIOPHARMA INC - 10-K - MANAGEMENT'S DISCU... [Published Street Sweeper - Aug 15 2014]
1 2 3
In Focus
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
  •  
Content Volume
Document Volume
Network
Network

Blogs

sort by: Date | Relevance
Array BioPharma Appoints Victor Sandor, M.D., A... [Published PR Newswire: General Business - Sep 11 2014]
BOULDER, Colo., Sept. 11, 2014 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY), a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients with cancer, today announced ...
Array BioPharma To Present At The Morgan Stanle... [Published PR Newswire: Health - Sep 03 2014]
BOULDER, Colo., Sept.  3, 2014 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Morgan Stanley 2014 Global Healthcare Conference in New York City.  The public is ...
Array BioPharma To Report Financial Results For... [Published PR Newswire: Health - Jul 28 2014]
BOULDER, Colo., July 28, 2014  Array BioPharma Inc. (Nasdaq:  ARRY) will report financial results for the fourth quarter and full year of fiscal 2014 and hold a conference call to discuss those results on Tuesday, August 12, 2014.  Ron Squarer, Chief ...
Array BioPharma To Present At The Wells Fargo S... [Published PR Newswire: General Business - Jun 11 2014]
BOULDER, Colo., June 11, 2014 /PRNewswire/ -- Array BioPharma Inc. (Nasdaq: ARRY) today announced that its Chief Executive Officer, Ron Squarer, will present at the Wells Fargo Securities 2014 Healthcare Conference in Boston.  The public is welcome ...
Array BioPharma, Biogen Idec enter drug discove... [Published PBR - News - May 29 2014]
US-based biopharmaceutical firm Array BioPharma has entered into collaboration agreement with Biogen Idec to discover and develop inhibitors targeting a new kinase for the treatment of autoimmune disorders. ...
1 2 3 4 5 6

Press Releases

sort by: Date | Relevance
Technical Summary on Biotech Equities -- Alkerm... [Published Financial Services - Aug 18 2014]
Array BioPharma Reports Financial Results For T... [Published Financial Services - Aug 12 2014]
Biotech Stocks Highlight -- Research on Celgene... [Published Financial Services - Jul 09 2014]
Study Updates, Market Activity, Preclinical Dat... [Published Financial Services - Jul 03 2014]
Health Care Sector Equities Coverage -- Researc... [Published Financial Services - Jun 06 2014]
1 2
Contact Us
Sales
Support


Freebase CC-BY Some image thumbnails are sourced from Freebase, licensed under CC-BY

Copyright (C) 2014 Silobreaker Ltd. All rights reserved.
The selection and placement of stories and images on any Silobreaker page are determined automatically by a computer program.
The time or date displayed reflects when an article was added to or updated in Silobreaker.